Progetto FRRB 2729068 - Identification of druggable targets using single cell characterisation of epigenetic dysregulation in high-grade serous ovarian cancer.

Dati del progetto

Nome e cognome della/del PI  Dr.ssa Aisling Coughlan
Acronimo  SC_HGSOC
ID progetto  2729068
Ente ospitante  Istituto Europeo di Oncologia S.r.l
Patologia di interesse  Carcinoma ovarico sieroso di alto grado
Area di Ricerca  Oncologia
Data di inizio Progetto  1° luglio 2021
Data di fine Progetto  31 Marzo 2022 (chiusura anticipata)
Importo assegnato  € 57.102,48
Tipo Progetto  Individuale


In the age of personalized medicine, ovarian cancer treatment has suffered from a critical lack of pre-clinical and clinical advances in identification of precision treatments. High-grade serous ovarian cancer accounts for over 70% of ovarian cancers. It is widely regarded as one of the most lethal gynecological malignancies with extremely poor survival rates and frequent relapse. In the clinic ovarian cancer is still treated with broadly targeted therapies, such as cisplatin. Therefore, rates of survival have not improved in over 30 years.

My project will begin to fill this void in ovarian cancer research by examining the key molecular determinants of the disease in order to identify new targets, or re-purpose existing approved drugs, for treatment. Therefore, this project will provide essential, and potentially prompt improvements in patient treatment for a disease that effects hundreds of thousands of women every year, with some of the highest rates observed in Central Europe.

To do this, I will use my unique position in one of the foremost ovarian cancer research groups in Europe, the Testa lab at the European Institute of Oncology in Milan, and the technological expertise therein to assess the epigenomic dysregulation of primary patient tumor tissue compared to the healthy tissue of origin for ovarian cancer. Epigenomic dysregulation is fast being realized as a hallmark of cancer as frequent mutations in epigenetic regulators have been found to drive tumorigenesis in a number of malignancies (i.e non-hodkins lymphoma, malignant rhabdoid tumours, pontine gliomas). Understanding the epigenome of ovarian cancer, and its healthy tissue counterpart, will allow for the identification of potential driver events in tumorigenesis and allow us to determine whether there can be any therapeutic benefits from any of a number of approved, and in-trial, epigenetic targeted small molecule inhibitors.